Eliminating artificial trans fatty acids in Argentina: estimated effects on the burden of coronary heart disease and costs by Rubinstein, Adolfo Luis et al.
Bull World Health Organ 2015;93:614–622 | doi: http://dx.doi.org/10.2471/BLT.14.150516
Research
614
Eliminating artificial trans fatty acids in Argentina: estimated effects 
on the burden of coronary heart disease and costs
Adolfo Rubinstein,a Natalia Elorriaga,a Osvaldo U Garay,a Rosana Poggio,a Joaquin Caporale,a Maria G Matta,a 
Federico Augustovski,a Andres Pichon-Rivierea & Dariush Mozaffarianb
Introduction
Artificial trans fatty acids (TFAs) are produced during the 
industrial processing of vegetable oils. The main source of such 
TFAs is partially hydrogenated vegetable oils.1 Consumption 
of TFAs alters the plasma lipid profile2,3 in such a way that it 
increases the risk of coronary heart disease (CHD).4 A 2% 
increase in energy intake from TFAs may increase the risk 
for a coronary event by up to 23%.3 Other potential adverse 
effects of TFAs include systemic inflammation, endothelial 
dysfunction, insulin resistance and arrhythmias.2
Based on these adverse effects, several countries have 
implemented policies to reduce industrial TFA consump-
tion,5 including nutrition guidelines, awareness programmes, 
voluntary or mandatory labelling of the TFA content of foods 
and health warning labels. Voluntary or legislated programmes 
to encourage industry to reformulate food products without 
TFAs and support the production of healthy alternatives have 
led to improvements in some countries.6 Mandatory food 
labelling in Canada7 and the United States of America8 have 
led some manufacturers to reduce or eliminate artificial TFAs 
in their products. However, many food products still contain 
such TFAs, especially when served in restaurants, schools, 
cafeterias and coffee shops.9
In Argentina, before 2004, artificial TFAs were present in 
most sweet or salty solid snack foods, such as biscuits.10 Be-
tween 2004 and 2014, Argentina implemented several policies 
to reduce artificial TFAs. After 2004, the industry voluntarily 
reformulated foods by replacing approximately 40% of TFAs 
from partially hydrogenated vegetable oils, mainly with TFA-
free sunflower oil with high-oleic acid content.11 Regulations 
enforcing mandatory labelling of artificial TFAs in food were 
introduced in 2006.12 With support from the Pan American 
Health Organization,13,14 the Argentine Ministry of Health 
negotiated with industry to eliminate artificial TFAs. The 
country’s food code was amended,15 such that, by the end of 
2014, industrially-produced TFAs in food should not exceed 
2% of total fats in vegetable oils and margarines and 5% of 
total fats in other foods (Fig. 1).16
Here we estimate the potential reductions in annual CHD 
events, disability-adjusted life years (DALYs) and associated 
health-care costs attributable to reductions in artificial TFAs 
in the diet.
Methods
The main inputs of the policy model for the analysis were: 
(i) the estimated baseline intake of TFAs before 2004; (ii) the 
types of alternative oils and fats used to replace TFAs; (iii) the 
effects of the improvements in plasma lipid profile on CHD 
risks and (iv) the health-care costs and DALYs saved due to 
averted fatal and nonfatal CHD events. Although our study is 
not a full economic evaluation, we used the CHEERS statement 
as a guide for reporting.17
Baseline intake of TFAs
To identify estimates of baseline TFA intake in Argentina and 
the fats used to improve the dietary fat profile between 2004 
and 2014, we conducted a literature search using MEDLINE, 
Embase, LILACS databases and official documents from the 
government, academia, industry and other public and private 
organizations. For the database searches, we used the search 
string “trans fat OR trans fatty acids OR partially hydrogenated 
oils OR partially hydrogenated fat AND Argentina”.
Objective To estimate the impact of Argentine policies to reduce trans fatty acids (TFA) on coronary heart disease (CHD), disability-adjusted 
life years (DALYs) and associated health-care costs.
Methods We estimated the baseline intake of TFA before 2004 to be 1.5% of total energy intake. We built a policy model including baseline 
intake of TFA, the oils and fats used to replace artificial TFAs, the clinical effect of reducing artificial TFAs and the costs and DALYs saved due 
to averted CHD events. To calculate the percentage of reduction of CHD, we calculated CHD risks on a population-based sample before 
and after implementation. The effect of the policies was modelled in three ways, based on projected changes: (i) in plasma lipid profiles; 
(ii) in lipid and inflammatory biomarkers; and (iii) the results of prospective cohort studies. We also estimated the present economic value 
of DALYs and associated health-care costs of coronary heart disease averted.
Findings We estimated that projected changes in lipid profile would avert 301 deaths, 1066 acute CHD events, 5237 DALYs and 17 million 
United States dollars (US$) in health-care costs annually. Based on the adverse effects of TFA intake reported in prospective cohort studies, 
1517 deaths, 5373 acute CHD events, 26 394 DALYs and US$ 87 million would be averted annually.
Conclusion Even under the most conservative scenario, reduction of TFA intake had a substantial effect on public health. These findings 
will help inform decision-makers in Argentina and other countries on the potential public health and economic impact of this policy.
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Because TFAs cannot be replaced 
on a 1:1 basis with other specific fatty ac-
ids, the unit of replacement was partially 
hydrogenated vegetable oils (comprised 
of various fatty acids, including TFAs). 
Thus, we evaluated both the total par-
tially hydrogenated vegetable oils con-
sumed and the usual proportion of TFAs 
in partially hydrogenated vegetable 
oils during 2004–2014. Our search was 
complemented by a consensus meeting 
of local experts and decision-makers 
including officials from the Ministry 
of Health, epidemiologists, nutrition-
ists, cardiologists and food engineers 
closely involved with the oils’ and fats’ 
suppliers of TFA replacements. They 
identified key estimates for the model, 
including the baseline intake of TFA, the 
proportion of TFA from ruminants and 
the replacement fats used by industry. 
Our central estimate of baseline TFA 
consumption in 2004 was 1.5% of total 
energy intake, with a lower limit of 1%18 
and an upper limit of 3%.14 The most 
common replacement oil was sunflower 
oil with high-oleic acid content (base 
case estimate 42.0%; range: 33.6–50.4), 
followed by interesterified fats (18.0%; 
range: 14.4–21.6) and beef tallow (12:0% 
range: 9.6–14.4; Table 1).
Changes in lipid profile
Improvements in the plasma lipid profile 
were expected to result in improvements 
in CHD risks. We assessed the relevant 
changes in plasma lipid profiles and 
other biomarkers of CHD risk based 
on meta-analyses of controlled dietary 
feeding trials.2,4 These estimates were 
used to drive projections of CHD risks, 
as outlined below.
CHD risk
To estimate reductions in CHD risk in 
the national population, we adapted a 
cardiovascular risk calculator, based on 
the Framingham risk equation and AS-
SIGN scores.30 We used individual level 
data on CHD risk factors from a national 
prospective cohort study.31 The study 
collected baseline data in 2011–2012 
on age, gender, smoking, systolic blood 
pressure, diabetes, left ventricular 
hypertrophy and the ratio total cho-
lesterol (TC)/high-density lipoprotein 
cholesterol (HDL-C). We combined 
these results with demographic data for 
Argentina using the 2010 census to cre-
ate a national CHD risk profile.32
According to the consensus of our 
expert panel, between 2004 and 2014, 
most of the partially hydrogenated veg-
etable oils in the diet were replaced by 
healthier fats. In 2011–2012, when the 
prospective cohort study took place, 
75% had been replaced. We used the 
observed TC/HDL-C ratio for each 
person in the 2011–2012 cohort study to 
calculate the expected TC/HDL-C ratios 
in 2004 and 2014. This calculation was 
based on the estimated baseline intake 
of TFA, the established effects of TFA on 
the TC/HDL-C ratio and the types and 
percentages of different fats/oils used 
by industry for replacements. Accord-
ing to the distributions of TC/HDL-C 
and other risk factors in the population 
in 2004 and 2014, we calculated the 
difference in the CHD risk between 
both years. 
Three alternative scenarios were 
analysed: (i) the effects of improved dietary 
fat profile on the ratio of TC/HDL-C and 
the relation of this ratio to the incidence 
of CHD (scenario 1);33 (ii) the CHD risk 
reduction through changes in other bio-
markers such as apolipoprotein (apo) B, 
ApoA1, lipoprotein (a), triglycerides and 
C-reactive protein (scenario 2); and (iii) the 
reported relation of TFA intake, substituted 
for carbohydrate intake, with the incidence 
of CHD in a pooled analysis of prospective 
studies and attributed to several patho-
physiological effects of TFA (scenario 3).2
Mortality from CHD
We estimated the annual number of deaths 
caused by CHD using national mortality 
statistics for 2010. We included deaths cod-
ed according to the International Classifi-
cation of Diseases (ICD-10) as I20–I25. We 
also assumed that 80% of the sudden deaths 
(ICD-10 code R96) were due to CHD.34,35 
We increased the number of CHD deaths 
by 21.5%, to account for the underreport-
ing of CHD as a cause of death.36
The difference in CHD risk predicted 
by the cardiovascular risk calculator was 
calibrated to the annual mortality from 
CHD. We assumed that the reduction in 
CHD deaths was proportional to the differ-
ence in estimated CHD risk. We also as-
sumed that the difference in 10 year-CHD 
risk was equally distributed in each year 
of the decade 2004–2014, by age and sex.
Morbidity from CHD
Total acute CHD events – fatal and 
non-fatal acute myocardial infarctions 
and acute coronary syndrome – were 
estimated from national data on CHD 
deaths based upon sex-specific 28 
day-CHD case-fatality rate for acute 
myocardial infarctions in southern 
Latin America (38% in women; 44% in 
men).36 For acute coronary syndrome, 
we used one-third of the case-fatality 
rate of acute myocardial infarctions, 
according to local sources.21 All values 
were calibrated by age-sex hospital case-
fatality rate in Argentina, obtained from 
the national hospital discharge registry 
for the public sector.37
Calculation of DALYs
We calculated DALY using individual 
equations for years of life lost (YLL) 
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limited to 2% of 
total fat content
For all other 
industrialized foods, TFA 
content limited to 5% of 
total fat content
RC: Ministerial Resolution; TFA: trans fatty acids.
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Table 1. Baseline TFA intake and replacements; epidemiological and cost inputs
Input Base case (range) Probability distribution Source
TFA intake related
TFA intake before 2004, E% 1.5 (1.0 to 3.0) Normal (mean: base; SD:10% of base) Consensus panel of experts14,18,19
Ruminant TFA, % 0.5% of E (0.15 to 0.75) (Beta; alpha: 2; beta: 3) Consensus panel of experts19
TFA content in PHVO, % 40.0 (30.0 to 50.0) Minimum extreme (min: 30; max: 50; 
likeliest: 45; scale: 4.5)
Consensus panel of experts
Replacement by sunflower oil with 
high-oleic acid content, %
42.0 (33.6 to 50.4) Normal (min: 0%; max: 100%; mean: 
42%; SD: 4%)
Consensus panel of experts
Replacement by beef tallow, % 12.0 (9.6 to 14.4) Proportionally adjusted to variations of 
% HOSO
Consensus panel of experts
Replacement by sunflower oil with 
high-stearic acid content, %
3.5 (2.8 to 4.2) Proportionally adjusted to variations of 
% HOSO
Consensus panel of experts
Replacement by sunflower oil and 
soybean oil, %
3.0 (2.4 to 3.6) Proportionally adjusted to variations of 
% HOSO
Consensus panel of experts
Replacement by interesterified fats, % 18.0 (14.4 to 21.6) Proportionally adjusted to variations of 
% HOSO
Consensus panel of experts
Replacement by palm oil, % 10.8 (8.6 to 12.9) Proportionally adjusted to variations of 
% HOSO
Consensus panel of experts
Replacement by lauric fats, % 10.8 (8.6 to 12.9) Proportionally adjusted to variations of 
% HOSO
Consensus panel of experts
Epidemiological
Effects of fats on TC/HDL-C
    Change TFA to  SFA −0.031 (−0.045 to −0.017) Normal (min: −0.045; max: −0.017; 
mean: −0.031; SD: 0.007)
Estimates from Mozaffarian and 
Clarke2
    Change TFA to MUFA −0.054 (−0.072 to −0.036) Normal (min: −0.072; max: −0.036; 
mean: −0.054; SD: 0.009)
Estimates from Mozaffarian and 
Clarke2
    Change TFA to PUFA −0.067 (−0.085 to −0.049) Normal (min: −0.085; max: −0.049; 
mean: −0.067; SD: 0.009)
Estimates from Mozaffarian and 
Clarke2
    Change SFA to MUFA −0.029 (−0.043 to −0.015) Normal (min: −0.043; max: −0.015; 
mean: −0.029; SD: 0.007)
Estimates from Mozaffarian and 
Clarke2
    Change SFA to  PUFA −0.035 (−0.049 to −0.021) Normal (min: −0.049; max: −0.021; 
mean: −0.035; SD: 0.007)
Estimates from Mozaffarian and 
Clarke2
    Change MUFA to  PUFA −0.006 (−0.020 to 0.008) Normal (min: −0.020; max: 0.08; mean: 
−0.020; SD :0.007)
Estimates from Mozaffarian and 
Clarke2
Effect of TFA replacements on other 
biomarkers (dietary trials)
2.92 (NA) Normal (min: 2.33; max: 3.5; mean: 
2.92; SD: 0.292)
Estimates from Mozaffarian and 
Clarke2
Effect of TFA replacements from 
cohort studies
5.04 (NA) Normal (min: 4.03; max: 6.05; mean: 
5.04; SD: 0.50)
Estimates from Mozaffarian and 
Clarke2
Case fatality rate AMI men, % 44.0 (35.2 to 52.8) Normal (min: 35.2%; max: 52.8%; 
mean: 44%; SD: 4.4%)
Salomon et al.20
Case fatality rate AMI women, % 38.0 (30.4 to 45.6) Normal (min: 30.4%; max: 45.6%; 
mean: 38%; SD: 3.8%)
Salomon et al.20
Case fatality rate ACS men, % 14.7 (11.7 to 17.6) Normal (min: 11.7%; max: 17.6%; 
mean: 14.7%; SD: 1.5%)
Estimated from Bazzino et al.21 
and Salomon et al.20
Case fatality rate ACS women, % 12.7 (10.1 to 15.2) Normal (min: 10.1%; max: 15.2%; 
mean: 12.7%; SD: 1.2%)
Estimated from Bazzino et al.21 
and Salomon et al.20
Total AMI deaths (n) 17 942 (NA) NA National statistics from MoH
Total CHD deaths (n) 24 875 (NA) NA National statistics from MoH
Cost
Cost per AMI event, US$ 5 765 (4 612 to 6 918) Normal (min: 0; mean: 5765.4; SD: 
576.5)
Health system costs average22–27
Cost per ACS event, US$ 6 416 (5 133 to 7 699) Normal (min: 0; mean: 6416; SD: 641.6) Health system costs average22–27
Annual costs per follow-up and 
treatment, US$
1 199 (959 to 1 439) Normal (min: 0; mean: 1199; SD: 119.9) Health system costs average22–27
Programmatic costs, US$ 129 001 (NA) NA Personal communication (MoH 
estimates)
ACS: acute coronary syndrome; AMI: acute myocardial infarction; CHD: coronary heart disease; E: energy intake; HOSO: high-oleic sunflower oil; MoH: ministry of health; 
MUFA: monounsaturated fatty acids; NA: not applicable; PHVO: partially hydrogenated vegetable oils; PUFA: polyunsaturated fatty acids; SD: standard deviation; SFA: 
saturated fatty acids; TC/HDL-C: total cholesterol/high-density lipoprotein cholesterol; TFA: trans fatty acids; US$: United States dollars.
Notes: Discount rates of 5% (range 0–10) were used.28 We used the average conversion rate during 2012, which was US$ 1 to 4.55 Argentine dollars.29
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and years of life with disability (YLD) 
according to the Global Burden of Dis-
ease Study.38 Briefly, YLL were calculated 
from national health statistics as the 
difference between local life expectancy 
and age at death. YLD is the product of 
disability weight and length of survival 
with disability for CHD events. Disabil-
ity weights for acute myocardial infarc-
tions and acute coronary syndrome were 
considered equal.20 Survival length was 
estimated using the software DISMOD 
II (World Health Organization (WHO), 
Geneva, Switzerland).39 Finally, DALYs 
were reported with discounting at a 
5% rate.
Costs
Cost inputs for the model were costs of 
acute CHD events, their follow-up and 
programmatic costs. A micro-costing 
approach was undertaken considering 
a health system perspective. Identifica-
tion of resources related to CHD events, 
quantities and utilization rates were ob-
tained from secondary local sources22–27 
and unit costs were derived from public, 
social security, and private tariffs of local 
health insurance institutions.
Costs of annual management of 
non-fatal CHD were calculated from 
the individual’s age at the episode to the 
average Argentine life expectancy, by 
age and gender, and discounted at a 5% 
annual rate.28 Finally, costs borne by the 
Ministry of Health for the implementa-
tion of annual surveillance and monitor-
ing of the compliance of the industry 
with the regulations were also estimated, 
and included costs of personnel, food 
analysis, and onsite training at food 
companies (Daniel Ferrante, Ministry of 
Health, personal communication, 2013).
All costs were converted to United 
States dollars, corresponding to the 
exchange rate of 2012.29
Sensitivity analyses
To evaluate parameter uncertainty, 
we performed sensitivity analyses ac-
cording to established guidelines.40 A 
deterministic sensitivity analysis was 
first performed to evaluate the uncer-
tainty related to specific parameters 
and their relative importance, depicted 
in a tornado analysis (Fig. 2). Ranges 
used for the parameters were extracted 
from the published literature or expert 
opinions. To assess global uncertainty, 
a probabilistic sensitivity analysis was 
performed, incorporating the main 
parameters and their distributions. 
Uncertainty in results was reported us-
ing 95% confidence intervals (CI) based 
on 1000 Monte Carlo simulations. All 
model inputs including TFA-related, 
epidemiological and costs parameters 
are shown in Table 1.
Results
Mortality, case-fatality and acute coro-
nary events per 100 000 population are 
shown in Table 2. Based on an estimated 
24 875 deaths from CHD in 2010, we 
estimated 83 830 CHD acute events in 
Argentina in people older than 34 years 
old. The results reported here assume a 
baseline consumption of 1.5% of total 
energy intake as TFA in 2004.
Based on the most conservative 
scenario of TFA replacements only in-
fluencing CHD events through changes 
in the TC/HDL-C ratio (scenario 1), we 
estimated 301 CHD deaths, 572 acute 
myocardial infarctions, 1066 acute 
CHD events and 5237 DALYs averted 
after 2014, compared with the expected 
events if the policy had not been imple-
mented (Table 3). In addition, more than 
US$ 17 million would be saved annually 
due to averted acute CHD events and 
lower costs of chronic treatment and 
follow-up.
When effects of TFA on CHD were 
calculated considering additional effects 
on other biomarkers (scenario 2), under 
the central estimate of 1.5% energy in-
take of TFA, a total of 3109 acute CHD 
events, 15 271 DALYs, and more than 
US$ 50 million in costs will be averted 
after 2014. If the effects of TFA on CHD 
were based on observed relationships 
with clinical events reported in prospec-
tive cohort studies (scenario 3), which 
may more fully account for the various 
effects of TFA, 1517 CHD deaths, 2884 
acute myocardial infarctions, 5373 acute 
CHD events and 26 394 DALYs were 
averted, resulting in estimated savings of 
USD 87 million (Table 3). The propor-
tion of events averted by the artificial 
TFA reduction policy in 2014 ranged 
from 1.26% (scenario 1) to 6.35% (sce-
nario 3) of total CDH events (Table 3). 
The estimated reductions in CHD were 
sensitive to the assumed baseline TFA 
intake in 2004 (Fig. 2).
Discussion
Given the estimated 84 000 annual 
CHD events in Argentina, at an annual 
incidence rate of almost 500 cases per 
100 000 adults older than 34 years old, 
the current policy of near elimination 
of industrial TFA might avert between 
1.3% and 6.35% of CHD events each 
year. The decrease would save between 
US$ 17 million and US$ 87 million in 
management of CHD complications and 
follow-up. Even in the most conservative 
scenario, the reduction of TFA intake 
has a substantial public health impact.
Although there is limited infor-
mation about the distribution of TFA 
intakes in subpopulations in most coun-
tries, it is likely that many subgroups, 
particularly low-income populations, 
could have mean TFA intakes consider-
ably higher than the population mean.41 
There might be subpopulations that con-
sume more industrially processed foods 
and fast foods with high-TFA content. 
Legislative strategies to ban artificial 
TFAs from foods have been more suc-
cessful than labelling or education as 
shown in Austria, Denmark, Iceland, 
Sweden, Switzerland and USA.9,41–43 In 
Denmark, the ban on artificial TFAs is 
thought to have played some part in the 
decrease of CHD.11
WHO has identified removal of ar-
tificial TFAs from the food supply as an 
intervention with favourable return of 
invested money to reduce the economic 
impact of noncommunicable diseases 
in low- and middle-income countries.44 
However, most such countries have not 
yet included the restriction of TFAs’ 
intake as a policy. Governments have 
been concerned about the feasibility, 
achievability and public health effect of 
removing them from the food supply. 
Thus, little is known about the potential 
effects on the reduction of CHD burden 
and cost savings that could be attribut-
able to the implementation of TFA-
reduction policies in these countries. 
Some middle-income countries such as 
Brazil,5 Costa Rica,5 India45 and Mexico5 
are following the Argentine example and 
are introducing policy and surveillance 
systems to monitor the content of TFA 
in foods.
A study modelling a legislative 
intervention to reduce artificial TFA 
to 0.5% of total energy intake in the 
United Kingdom of Great Britain and 
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Northern Ireland, estimated that ap-
proximately 2700 deaths annually would 
be prevented, saving the equivalent of 
approximately 235 million pounds ster-
ling a year.46 Another modelling study 
estimated a similar potential impact 
of this policy in Ireland.47 Unlike these 
studies, our model is based on individual 
data on CHD risk from an Argentine 
population-based sample, calibrated 
with national statistics, as well as with 
local data on dietary fat profiles. More-
over, our study is modelling the impact 
of a policy that is being implemented.
Potential limitations of this study 
should be considered. First, to calculate 
CHD risk in Argentina we used a cardio-
vascular risk calculator.30 The calculator 
is based on equations developed a couple 
of decades ago when the CHD incidence 
was higher. This could overestimate 
absolute risk in light of secular trends 
towards lower CHD risk.48 On the other 
hand, these risk equations are widely 
validated for predicting CHD risk. Over-
estimation would not likely influence 
our estimates of proportional risk reduc-
tion, since relative risks were calibrated 
with Argentine absolute risks. Second, 
we used the global percentage estimates 
to adjust for underreporting of mortality 
from CHD. Third, costs of food reformu-
lation by industry were not considered, 
based on our health system perspective. 
Yet, potential incremental costs for in-
dustry to reduce artificial TFA may be 
at least partly offset by higher pricing or 
sales due to marketing advantages.11 In 
the USA, switching to newer frying oils 
that were free of TFA was cost neutral.38 
Fourth, we did not have precise data on 
baseline TFA, the level of which would 
influence results. Conversely, our nutri-
tional inputs, particularly those related 
to the TFA baseline intake before 2004, 
and the partially hydrogenated vegetable 
oils’ replacements used by the industry 
thereafter, were obtained after a thor-
ough literature search for sources of 
TFA in Argentina. This information was 
reviewed by experts to reach consensus 
on information gaps to derive a reason-
Fig. 2. Deterministic sensitivity analysis of the parameters used to estimate the impact 
of trans fatty acids’ regulations in Argentina, 2004–2014
Averted effect compared to base value (%)
-100 -50 0 50 100 150 200
TFA intake %
TFA from ruminants
Effects of fatty acids on TC/HDL-C (TFA to MUFA)
Discount rate %
Replacement with high-oleic acid sunflower oil %
Effects of fatty acids on TC/HDL-C (TFA to SFA)
Case fatality rate AMI women %
Costs per follow-up and treatment US$
TFA  content in PHVO
Effects of fatty acids on TC/HDL-C (TFA to PUFA)
Inputs
Impact on cost (upper range)
Impact on CHD events (upper range) Impact on CHD events (lower range)
Impact on cost (lower range)
AMI: acute myocardial infarction; CHD: coronary heart disease; MUFA: monounsaturated fatty acids; 
PHVO: partially hydrogenated vegetable oils; PUFA: polyunsaturated fatty acids; SFA: saturated fatty acids; 
TC/HDL-C: total cholesterol/high-density lipoprotein cholesterol; TFA: trans fatty acids; US$: United States 
dollars.
Table 2. Cardiovascular disease events, Argentina, 2010
Event No. of persons at riska No. of events Incidence 
per 100 000 
population




AMI – 23 669 302.713 10 414 133 44.0
Sudden death – 867 11.09 867 11 100.0
ACS – 21 649 276.87 3 140 40 14.5
Total 7 818 921 46 185 590.681 14 421 184 31.2
Women
AMI – 19 809 220.08 7 527 84 38.0
Sudden death – 652 7.25 652 7 100.0
ACS – 17 184 190.91 2 274 25 13.2
Total 9 000 933 37 645 418.24 10 453 116 27.8
All
AMI – 43 478 258.49 17 941 107 41.3
Sudden death – 1 519 9.04 1 520 9 100.0
ACS – 38 833 2687.53 5 414 32 12.0
Total 16 819 854 83 830 498.40 24 875 148 29.7
AMI: acute myocardial infarction; ACS: acute coronary syndrome.
a  Based on 2010 national census.
b  Reported by Ministry of Health 2010.
C  Average case-fatality rate of an age-calibrated function based on Salomon et al.20 and Bazzino et al.21
Note: Population older than 34 years.
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able central estimate and appropriate 
upper and lower bounds.
In conclusion, our findings sug-
gest that artificial TFA reduction 
interventions, as an example of a 
nutritional policy aimed to reach the 
overall population, have beneficial 
impact on the total burden of CHD 
in Argentina. These findings will 
help inform decision-makers in both 
Argentina and other countries on the 
potential public health and economic 
impact of this policy. ■
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صخلم
 ةيئاعولا ةيبلقلا ضارملأا ءبع لىع ةيريدقتلا راثلآا :ينتنجرلأا في ةيعانصلا ةلوحتلما ةينهدلا ضاحملأا لىع ءاضقلا
اتهاقفنو
 ضاحملأا  نم  دحلل  ةينيتنجرلأا  تاسايسلا  رثأ  ريدقت  ضرغلا
 ،)CHD(  يئاعولا  يبلقلا  ضرم  لىع  )TFA(  ةلوحتلما  ةينهدلا
 ،)DALYs(  زجعلا  ددم  باستحاب  ةححصلما  رمعلا  تاونسو
.ابه ةطبترلما ةيحصلا ةياعرلا تاقفنو
 ضاحملأا نم سياسلأا لوخدلما ةبسن نأ لىإ انتاريدقت يرشت ةقيرطلا
 لياجمإ  نم  1.5%  غلبت  تناك  2004  ماع  لبق  ةلوحتلما  ةينهدلا
 نمضتت  ةسايسل  جذومن  عضوب  انمق  ،كلذل  .ةقاطلا  لوخدم
 تويزلاو  ةلوحتلما  ةينهدلا  ضا�حملأا  نم  سيا�سلأا  لوخدلما
 ،ةلوحتلما  ةينهدلا  ضاحملأا  كلت  لمح  لحتل  ةمدختسلما  نوهدلاو
 فيلاكتلاو  ةلوحتلما  ةينهدلا  ضاحملأا  ليلقتل  يكينيلكلإا  رثلأاو
Table 3. Annual CHD deaths and CHD acute events and DALYs averted, and costs savings attributable to the full implementation of the 
policy
Scenario No. of CHD 
deaths averted 
(95% CI)
No of AMI 
deaths averted 
(95% CI)




CHD events, % 
(95% CI)






Scenario 1: Based only on the 
effect of TFA replacements on 
the ratio of TC/HDL-C
Base case – 1.5% baseline TFA 
intake
301 (233 to 
433)
572 (443 to 
823)
1 066 (875 to 
1 623)
1.26 (1.03 to 
1.92)
5 237 (4 461 to 
8 282)
17.3 (14.5 to 
28.7)
Lower limit 1.0% 151 (109 to 
273)
286 (207 to 
519)
533 (408 to 
1 023)
0.63 (0.48 to 
1.21)
2 619 (2 081 to 
5 220)
8.6 (6.7 to 
17.9)
Upper limit 3.0% 752 (571 to 
937)
1 429 (1 086 
to 1 781)
2 663 (2 142 to 
3 515)
3.15 (2.53 to 
4.15)
13 087 (10 929 to 
17 941)
43.2 (35.0 to 
62.4)
Scenario 2: Scenario 1 plus the 
effects of TFA replacements 
on other CHD biomarkers in 
controlled trials
Base case – 1.5% baseline TFA 
intake
878 (652 to 
1 328)
1 668 (1 238 
to 2 523)
3 109 (2 442 to 
4 978)
3.67 (2.89 to 
5.88)
15 271(12 459 to 
25 395)
50.5 (40.5 to 
87.1)
Lower limit 1.0% 439 (307 to 
822)
835 (584 to 
1 563)
1 555 (1 190 to 
2 984)
1.84 (1.41 to 
3.53)
7 637 (5 871 to 
15 725)
25.2 (19.7 to 
52.2)
Upper limit 3.0% 2 192 (1 577 to 
2 871)
4 167 (2 997 
to 5 458)
7 764 (6 245 to 
10 249)
9.17 (7.38 to 
12.11)
38 163 (30 165 to 
54 987)
126. 2 (102.2 
to 182.1)
Scenario 3: Based on the 
observed relationship of TFA 
replacements with clinical CHD 
events in prospective cohort 
studies
Base case - 1,5% baseline TFA 
intake
1 517 (1 118 to 
2 285)
2 884 (2 124 
to 4 343)
5 373 (4 191 to 
8 568)
6.35 (4.95 to 
10.12)
26 394 (21 376 to 
43 713)
87.3 (69.1 to 
150.8)
Lower limit 1.0% 759 (525 to 
1 427)
1 442 (997 to 
2 712)
2 687 (2 056 to 
5 158)
3.18 (2.43 to 
6.09)
13 199 (10 031 to 
27 294)
43.67 (34.0 to 
90.2)
Upper limit 3.0% 3 788 (2 708 to 
4 944)
7 202 (5 148 
to 9 399)
13 419 (10 794 
to 17 713)
15.86 (12.76 to 
20.93)




AMI: acute myocardial infarction; CHD: coronary heart disease; CI: confidence interval; DALY: disability-adjusted life-years; TC/HDL-C: total cholesterol/high-density 
lipoprotein cholesterol; TFA: trans fatty acids; US$: United States dollars.
Notes: We used the average conversion rate during 2012, which was US$ 1 to 4.55 Argentine dollars.29 Biomarkers included apolipoproteins, triglycerides, lipoprotein (a) 
and C-reactive protein.
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 اهيرفوت متي يتلا زجعلا ددم باستحاب ةححصلما رمعلا تاونسو
 متي يكلو .ةيئاعولا ةيبلقلا ضارملأاب ةباصلإا عئاقو شياتح ببسب
 ،ةيئاعولا  ةيبلقلا  ضارملأاب  ةباصلإا ليلقتل  ةيوئلما  ةبسنلا  باسح
 ةيناكس ةيحشر لىإ دنتست ةنيع لىع ضارملأا كلت رطامخ انبستحا دقف
 تاسايسلا  رثلأ  جذمان  عضو  متو  .اهدعبو  ةسايسلا  ذيفنت  لبق
 طمانأ  في  )1(  :ةعقوتلما  تايريغتلا  لىإ  ًادانتسا  قرط  ثلاث  عابتاب
 ةيباهتللاا  ةيويلحا  تاددحلماو  نوهدلا  في  )2(و  ،امزلابلا  نوهد
 تاساردلا  جئاتن  )3(و  ،Inflammatory biomarkers(
 ماك  .)Prospective cohort studies(  ةيقابتسلاا  ةيبارتلأا
 ةححصلما رمعلا تاونسل ةيلالحا ةيداصتقلاا ةميقلل اًريدقت انعضو
 ةيحصلا ةياعرلل فيلاكت نم ابه طبتري امو زجعلا ددم باستحاب
.هب ةباصلإا شياتح مت يذلا يئاعولا بلقلا ضرلم
 نوهدلا  طمن  في  ةعقوتلما  تايريغتلا  نأ  لىإ  انتاريدقت  يرشت  جئاتنلا
 ةباصإ  ةعقاو  1066و  ،ةا�فو  ةلاح  301  شياتح  لىإ  يدؤيس
 ةنس 5237  ذاقنإو  ،ةيئاعولا  ةيبلقلا  ضارملأا  نم  ةداح تلااحب
 يكيرمأ رلاود نويلم 17و ،زجعلا ددم باستحاب ةححصم رمع
 لوخدلم ةيبنالجا راثلآا لىع ًءانبو .ةيحصلا ةياعرلا تاقفن نم اًيونس
 تاساردلا في انهأشب ريراقت تدرو يتلا ةلوحتلما ةينهدلا ضاحملأا
 5373و  ،ةافو  ةلاح  1517  بنتج  متيسف  ،ةيقابتسلاا  ةيبارتلأا
 ذاقنإو ،ةيئاعولا ةيبلقلا ضارملأا نم ةداح تلااحب ةباصإ ةعقاو
 نويلم  87و  ،زجعلا  ددم  باستحاب  ةححصم  رمع  ةنس  26,394
.اًيونس يكيرمأ رلاود
 دحلل ناك دقف ،اًظفتح رثكلأا تاهويرانيسلا لظ في ىتح جاتنتسلاا
 .ةماعلا ةحصلا لىع يربك رثأ ةلوحتلما ةينهدلا ضاحملأا لوخدم نم
 عانصل ةيفاكلا تامولعلما ميدقت في ديفت نأ جئاتنلا هذه نأش نمو
 لىع  لمتحلما  رثلأا  نأشب  نادلبلا  نم  اهيرغو  ينتنجرلأاب  رارقلا




(TFA) 的政策对冠心病 (CHD)、残疾调整生命年 (DALY) 
和相关医疗保健成本产生的影响。




脂肪酸 (TFA) 的临床效果，以及因预防冠心病 (CHD) 
事件而节约的成本和残疾调整生命年 (DALY)。 为了
计算冠心病 (CHD) 减少的百分比，我们在实施前后基
于研究人群计算了冠心病 (CHD) 风险。 根据预测的
变化，以三种方式模拟政策的影响： (i) 血浆中的血脂；
(ii) 脂质和炎性标记物 ；以及 (iii) 前瞻性群组研究的结
果。 我们还估计了残疾调整生命年 (DALY) 在当下的
经济价值，以及预防冠心病的相关医疗保健成本。
结果 我们估计，血脂变化预计每年将会避免 301 人死
亡、1066 例急性冠心病 (CHD) 事件和 5237 个残疾调
整生命年 (DALY)，并可节约 1700 万美元 (US$) 的医
疗保健成本。 基于前瞻性群组研究中所报告的摄入反
式脂肪酸 (TFA) 后产生的不良影响，每年可防止 1517 
人死亡、5373 例急性冠心病 (CHD) 事件和 26 394 个残
疾调整生命年 (DALY)，并可节约 8700 万美元 (US$)。
结论 即使是在最为保守的情况中，减少摄入反式脂肪




Élimination des acides gras trans artificiels en Argentine: effets estimés sur la charge des cardiopathies coronariennes et sur 
les coûts associés
Objectif Estimer l’impact des politiques argentines de réduction des 
acides gras trans (AGT) sur les cardiopathies coronariennes (CC), les 
années de vie corrigées du facteur incapacité (AVCI) et les coûts des 
soins de santé associés.
Méthodes Nous sommes partis d’une estimation de l’apport de 
référence en AGT avant 2004 représentant 1,5% de l’apport énergétique 
total. Nous avons conçu un modèle pour ces politiques, en intégrant 
cet apport en AGT de référence, les huiles et graisses utilisées pour 
remplacer les AGT artificiels, les effets cliniques de la réduction des AGT 
artificiels, les coûts associés ainsi que les AVCI épargnées du fait des 
accidents coronariens évités. Pour calculer le pourcentage de réduction 
des CC, nous avons calculé les risques de CC sur un échantillon en 
population, avant et après la mise en œuvre de ces politiques. Les effets 
de ces politiques ont été modélisés de trois manières, en fonction des 
changements projetés: (i) au niveau des profils lipidiques plasmatiques; 
(ii) au niveau des biomarqueurs lipidiques et inflammatoires et (iii) 
en fonction des résultats des études prospectives de cohortes. Nous 
avons également estimé la valeur économique actuelle des AVCI et 
du coût des soins de santé associés correspondant aux cardiopathies 
coronariennes évitées.
Résultats Selon nos estimations, les changements projetés des profils 
lipidiques devraient permettre d’éviter 301 décès, 1 066 accidents 
coronariens aigus, 5 237 AVCI et 17 millions de dollars des États-
Unis d’Amérique ($US) de dépenses annuelles en soins de santé. À 
partir des effets défavorables des apports en AGT indiqués dans les 
études prospectives de cohortes, ce sont 1 517 décès, 5 373 accidents 
coronariens aigus, 26 394 AVCI et 87 millions de $US de dépenses qui 
pourraient être évités chaque année.
Conclusion Même dans le scénario le plus prudent, la réduction de 
l’apport en AGT a un effet considérable sur la santé publique. Ces 
résultats permettront d’informer les décideurs en Argentine et dans 
d’autres pays sur les impacts potentiels de ce type de politiques sur le 
plan économique et en termes de santé publique.
Bull World Health Organ 2015;93:614–622| doi: http://dx.doi.org/10.2471/BLT.14.150516 621
Research
Trans fats in ArgentinaAdolfo Rubinstein et al.
Резюме
Устранение искусственных трансжирных кислот в Аргентине: ожидаемое воздействие на бремя 
ишемической болезни сердца и на сопутствующие расходы
Цель Оценить воздействие применяемых в Аргентине политик 
по уменьшению количества трансжирных кислот в пище (ТЖК) 
на развитие ишемической болезни сердца (ИБС), на количество 
лет жизни, утраченных в результате болезни, и на сопутствующие 
расходы на здравоохранение.
Методы По нашим оценкам, до 2004 года 1,5% общего количества 
пищевых калорий приходилось на ТЖК, и эту величину мы 
приняли за базовый уровень. Мы разработали модель политики, 
включающую базовый уровень потребления ТЖК, жиры и 
масла, которыми планировалось заменить искусственные ТЖК, 
клинический эффект от снижения уровня ТЖК, а также уровень 
экономии и количество спасенных лет жизни в результате 
предотвращения случаев ИБС. Для расчета процентной 
доли снижения ИБС были рассчитаны риски возникновения 
ИБС для популяционной выборки до и после реализации 
вышеуказанной политики. Эффект от применения политик 
моделировался тремя путями в зависимости от предполагаемых 
изменений: (i) по профилям липидов в плазме, (ii) по липидам и 
биомаркерам воспалительного процесса и (iii) по результатам 
проспективных когортных исследований. Мы также оценили 
текущее экономическое значение спасенных лет жизни и 
уменьшения сопутствующих расходов на лечение в случае 
предотвращения ишемической болезни сердца.
Результаты По предварительным оценкам, предполагаемые 
изменения в профиле липидов позволят предотвратить 301 
смерть, 1066 острых случаев ИБС, спасти 5237 лет жизни 
и сэкономить 17 млн долл. США на ежегодных расходах 
на здравоохранение. Если исходить из неблагоприятных 
последствий употребления пищевых ТЖК, о которых сообщалось 
в проспективных когортных исследованиях, то ежегодно можно 
будет предотвратить 1517 смертей, 5373 острых случая ИБС, 
спасти 26 394 года жизни и сэкономить 87 млн долл. США на 
медицинских расходах.
Вывод Даже при самом неблагоприятном сценарии уменьшение 
употребления ТЖК в значительной мере повлияет на здоровье 
населения. Эти результаты помогут информировать ответственных 
лиц в Аргентине и других странах о потенциальном воздействии 
такой политики на здоровье населения и национальную 
экономику.
Resumen
La eliminación de los ácidos grasos de tipo trans artificiales en Argentina: efectos estimados en la carga de cardiopatías 
coronarias y los costes
Objetivo Estimar el impacto de las políticas argentinas para la reducción 
de los ácidos grasos de tipo trans (AGT) en las cardiopatías coronarias, 
los años de vida ajustados en función de la discapacidad (AVAD) y los 
costes de la atención sanitaria asociados.
Métodos Se estimó que la ingesta base de AGT antes de 2004 era 
de 1,5% de la ingesta de energía total. Se construyó un modelo 
de política que incluía la ingesta base de AGT, los aceites y grasas 
utilizados para reemplazar los AGT artificiales, el efecto clínico de 
reducir los AGT artificiales y el coste y los AVAD salvados debido a los 
casos de cardiopatías coronarias evitadas. Para calcular el porcentaje 
de reducción de cardiopatías coronarias, se calcularon los riesgos de 
cardiopatías coronarias en un modelo basado en la población antes y 
después de la implementación. El efecto de las políticas fue modelado 
de tres formas, en base a cambios estimados: (i) perfiles de plasma 
de lípidos; (ii) marcados biológicos inflamatorios de lípidos; y (iii) los 
resultados de estudios de cohortes prospectivos. También se estimó el 
valor económico actual de los AVAD y los costes de atención sanitaria 
asociados a las cardiopatías coronarias evitadas.
Resultados Se estimó que los cambios estimados en el perfil de lípidos 
evitarían 301 muertes, 1.066 casos graves de cardiopatías coronarias, 
5.237 AVAD y 17 millones de dólares estadounidenses (USD) en atención 
sanitaria cada año. Basándose en los efectos adversos del consumo 
de AGT de los estudios de cohortes prospectivos, se evitarían 1.517 
muertes, 5.373 casos graves de cardiopatías coronarias, 26.394 AVAD y 
87 millones de USD cada año.
Conclusión Incluso bajo el escenario más conservador, la reducción 
del consumo de AGT tuvo un efecto sustancial en la salud pública. 
Estos resultados ayudarán a informar a los responsables de la toma 
de decisiones en Argentina y otros países sobre el potencial impacto 
económico y de salud pública de esta política.
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